Raymond James Cuts Danaher (NYSE:DHR) Price Target to $275.00

Danaher (NYSE:DHR) had its price objective decreased by Raymond James from $300.00 to $275.00 in a research note published on Tuesday,Benzinga reports. Raymond James currently has an outperform rating on the conglomerate’s stock.

DHR has been the topic of a number of other reports. Robert W. Baird dropped their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. TD Cowen raised their price objective on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Scotiabank assumed coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research note on Thursday, October 31st. Finally, Citigroup lowered their price objective on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Price Performance

Shares of DHR stock opened at $245.73 on Tuesday. The stock has a 50 day moving average price of $234.90 and a 200 day moving average price of $253.47. Danaher has a 52-week low of $225.42 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm has a market capitalization of $177.49 billion, a P/E ratio of 46.90, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.02 earnings per share. As a group, sell-side analysts predict that Danaher will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s payout ratio is 20.61%.

Institutional Investors Weigh In On Danaher

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Coronation Fund Managers Ltd. boosted its position in Danaher by 29.9% in the second quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock valued at $1,596,000 after buying an additional 1,470 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Danaher by 7.9% in the second quarter. ProShare Advisors LLC now owns 96,531 shares of the conglomerate’s stock worth $24,118,000 after acquiring an additional 7,091 shares during the period. Mount Yale Investment Advisors LLC raised its holdings in shares of Danaher by 43.8% during the second quarter. Mount Yale Investment Advisors LLC now owns 2,641 shares of the conglomerate’s stock worth $660,000 after purchasing an additional 805 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Danaher by 12.1% during the second quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the conglomerate’s stock valued at $424,000 after purchasing an additional 165 shares during the period. Finally, DRW Securities LLC purchased a new stake in Danaher in the second quarter valued at $385,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.